Monte Rosa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
GLUE$10.58+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $128,101 | $54,912 |
| Marketable securities | 104,312 | 207,914 |
| Other receivables | 505 | 7,656 |
| Prepaid expenses and other current assets | 3,294 | 4,444 |
| Current restricted cash | — | 960 |
| Total current assets | 236,212 | 275,886 |
| Property and equipment, net | 33,803 | 27,075 |
| Operating lease right-of-use assets | 28,808 | 34,832 |
| Restricted cash, net of current | 4,580 | 4,318 |
| Other long-term assets | 352 | 278 |
| Total assets | $303,755 | $342,389 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,152 | $7,862 |
| Accrued expenses and other current liabilities | 14,600 | 14,580 |
| Current deferred revenue | 17,678 | — |
| Current portion of operating lease liability | 3,162 | 3,127 |
| Total current liabilities | 46,592 | 25,569 |
| Deferred revenue, net of current | 32,323 | — |
| Defined benefit plan liability | 2,713 | 1,533 |
| Operating lease liability | 42,877 | 43,874 |
| Total liabilities | 124,505 | 70,976 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023; and 500,000,000 shares authorized, 49,445,802 shares issued and 49,323,531 shares outstanding as of December 31, 2022 | 5 | 5 |
| Additional paid-in capital | 547,857 | 503,696 |
| Accumulated other comprehensive loss | (2,724) | (1,752) |
| Accumulated deficit | (365,888) | (230,536) |
| Total stockholders’ equity | 179,250 | 271,413 |
| Total liabilities and stockholders’ equity | $303,755 | $342,389 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.